What is the pathophysiology of attention-deficit/hyperactivity disorder (ADHD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ADHD Pathophysiology

ADHD is a chronic neurodevelopmental disorder with multifactorial etiology characterized by complex but high heritability, executive dysfunction across multiple cognitive domains, and structural/functional abnormalities predominantly in frontostriatal, frontoparietal, and ventral attention brain networks 1.

Genetic and Etiological Basis

ADHD demonstrates complex but high heritability with multifactorial etiology 1. The disorder is not caused by a single gene but likely involves many genes of small individual effect 2. This genetic complexity contributes to the heterogeneity observed in clinical presentation and treatment response.

Neurobiological Mechanisms

Brain Network Abnormalities

The pathophysiology centers on dysfunction in larger-scale brain networks, specifically:

  • Frontostriatal networks (lateral prefrontal cortex, dorsal anterior cingulate cortex, caudate nucleus, putamen)
  • Frontoparietal networks
  • Ventral attention networks 1

Structural imaging reveals widespread volume reductions throughout cerebrum and cerebellum, including:

  • Total cerebral volume reduction
  • Prefrontal cortex volume reduction
  • Basal ganglia (striatum) reduction
  • Dorsal anterior cingulate cortex reduction
  • Corpus callosum reduction
  • Cerebellar vermis reduction 3

Functional imaging demonstrates that individuals with ADHD activate more diffuse brain areas during cognitive tasks compared to controls, with hypoactivation specifically in the dorsal anterior cingulate cortex, frontal cortex, and basal ganglia 3.

Neurotransmitter Dysfunction

Dopamine and norepinephrine dysregulation forms the neurochemical foundation of ADHD pathophysiology 1. The dopaminergic hypothesis is supported by:

  • Fronto-subcortical dysfunction in dopamine-rich brain regions 4
  • Altered dopamine cell firing activity associated with reinforcing events 2
  • Failure of dopamine signal transfer to earlier behavioral sequence time-points as reinforcement becomes predictable 2
  • Evidence from pharmacological response to stimulants (methylphenidate and amphetamine) that enhance dopamine and norepinephrine transmission 1

Recent research also implicates NMDA receptor dysfunction and abnormal D-serine metabolism in the prefrontal cortex, suggesting glutamatergic system involvement 5.

Cognitive and Executive Dysfunction

Patients exhibit executive deficits across multiple cognitive domains:

  • Visuospatial and verbal working memory impairment
  • Inhibitory control deficits (poor behavioral inhibition)
  • Vigilance problems
  • Planning difficulties
  • Reward regulation abnormalities 1

These deficits reflect both:

  • "Hot" executive functions (affective aspects): behavioral inhibition and attention, associated with ventral/medial prefrontal cortex and anterior cingulate cortex
  • "Cool" executive functions (cognitive aspects): self-regulation, working memory, planning, cognitive flexibility, associated with dorsolateral prefrontal cortex 3

Motivational Abnormalities

Altered response to reinforcement plays a central role in ADHD symptoms, with sensitivity to delay of reinforcement being a particularly reliable finding 2. This motivational dysfunction contributes significantly to the behavioral manifestations of the disorder.

Clinical Heterogeneity

The pathophysiology produces high variability on both interindividual and intraindividual levels 1. This heterogeneity manifests as:

  • Different symptom presentations (inattentive, hyperactive-impulsive, combined subtypes)
  • Variable persistence into adulthood (approximately 2.5% adult prevalence) 1
  • Gender differences in presentation (boys show more hyperactive/externalizing symptoms; girls more internalizing comorbidities) 6
  • High rates of psychiatric comorbidities (conduct disorder, oppositional defiant disorder, anxiety, depression) and somatic comorbidities (obesity) 1

Functional Impact

The underlying neurobiological abnormalities result in impairment across multiple domains that negatively affect long-term outcomes including academic achievement, employment status, social relationships, and increased risk of traffic accidents when inadequately treated 1. Core symptoms are frequently accompanied by additional problems such as sleep disturbances, depressed mood, and oppositional behavior, further reducing psychosocial functioning 1.

Important Clinical Considerations

The pathophysiology explains why symptoms persist through adolescence into adulthood in the majority of cases, though hyperactive/impulsive symptoms tend to decline while inattentive symptoms persist 6. Understanding this chronic neurodevelopmental nature is essential for appropriate long-term management planning.

The neurobiological basis also clarifies the mechanism of action for first-line pharmacotherapies: psychostimulants enhance dopamine and norepinephrine impact, increasing prefrontal cortex efficiency and optimizing executive and attentional function 1. This directly addresses the core neurotransmitter deficits underlying the disorder.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.